Kiniksa initiated with a Buy at TD Cowen

TD Cowen initiated coverage of Kiniksa (KNSA) with a Buy rating and $60 price target The firm says Kiniksa is at a “pivotal stage” as Arcalyst’s launch continues to ramp while KPL-387 could offer more favorable dosing. This could extend the franchise and significantly improve the company’s earnings, the analyst tells investors in a research note.